Author | James Gulley, MD, PhD | OncLive

Author | James Gulley, MD, PhD

Articles

Dr. Gulley on Take Home Message With Olaparib Plus Durvalumab in mCRPC

February 17, 2018

Video

James Gulley, MD, PhD, chief, Genitourinary Malignancies Branch, and director, Medical Oncology Service at the National Cancer Institute, discusses the take-home message with the combination of olaparib (Lynparza) plus durvalumab (Imfinzi) in metastatic castration-resistant prostate cancer.

Dr. Gulley Discusses a Phase II Study of Olaparib and Durvalumab in mCRPC

February 10, 2018

Video

James Gulley, MD, PhD, chief, Genitourinary Malignancies Branch, and director, Medical Oncology Service, at the National Cancer Institute, discusses a phase II study of olaparib (Lynparza) and durvalumab (Imfinzi) in metastatic castration-resistant prostate cancer (mCRPC) in an unselected patient population, presented at the 2018 Genitourinary Cancers Symposium.

x